At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Salsalatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study to Determine the Effects of 12 Weeks of Treatment With Salsalate on Measures of Peripheral Neuropathy in Type 1 Diabetes
In Brief
A Phase 2 clinical trial evaluating Salsalate for Peripheral Neuropathy and Type 1 Diabetes. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This 12 week study will examine the effects of daily Salsalate treatment on markers of neuropathic pain and intra-epidermal nerve fiber density. the study is being done in people with type 1 diabetes with signs and symptoms of peripheral neuropathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Neuropathy, Type 1 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedNov 2011
Primary CompletionApr 2012
Study CompletionSep 2014
TodayJul 2026
First PostedNov 28, 2011
Enrollment StartNov 1, 2011
Primary CompletionApr 1, 2012
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.6 years ago
Interventions
Salsalatedrug
Salsalate 3 grams daily (1 gram TID with meals)